1-5 of 5
Ronald de Wit
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1–S Transition

Stefan A.J. Buck, Annelies Van Hemelryk, Corrina de Ridder, Debra Stuurman, Sigrun Erkens-Schulze, Sem van ’t Geloof, Wilma J. Teubel, Stijn L.W. Koolen, Elena S. Martens-Uzunova, Martin E. van Royen, Ronald de Wit, Ron H.J. Mathijssen, Wytske M. van Weerden
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (5): 711–720.
https://doi.org/10.1158/1535-7163.MCT-23-0420
Published: 02 May 2024
View article titled, Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G<sub>1</sub>–S Transition
Open the PDF for Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G<sub>1</sub>–S Transition in another window
Includes: Supplementary data
Journal Articles

Abstract C68: SLCO1B3 influences taxane-response in prostate cancer

Ellen S. de Morree, Rene Bottcher, Robert J. van Soest, Ashraf Aghai, Corrina M. de Ridder, Alice A. Gibson, Ron HJ Mathijssen, Herman Burger, Erik AC Wiemer, Alex Sparreboom, Wytske M. van Weerden, Ronald de Wit
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C68.
https://doi.org/10.1158/1535-7163.TARG-15-C68
Published: 01 December 2015
View article titled, Abstract C68: SLCO1B3 influences taxane-response in prostate cancer
Journal Articles

Abstract A99: Docetaxel-resistance can be overcome by enhancing intratumoral taxane concentrations to a threshold level for efficacy.

Ellen S. de Morree, Corrina M. de Ridder, Peter de Bruijn, Herman Burger, Erik A.C. Wiemer, Ron H.J. Mathijssen, Ronald de Wit, Wytske van Weerden
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A99.
https://doi.org/10.1158/1535-7163.TARG-13-A99
Published: 01 November 2013
View article titled, Abstract A99: Docetaxel-resistance can be overcome by enhancing intratumoral taxane concentrations to a threshold level for efficacy.
Journal Articles

Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel

Tristan M. Sissung, Romano Danesi, Douglas K. Price, Seth M. Steinberg, Ronald de Wit, Muhammad Zahid, Nilesh Gaikwad, Ercole Cavalieri, William L. Dahut, Dan L. Sackett, William D. Figg, Alex Sparreboom
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (1): 19–26.
https://doi.org/10.1158/1535-7163.MCT-07-0557
Published: 17 January 2008
View article titled, Association of the <em>CYP1B1*3</em> allele with survival in patients with prostate cancer receiving docetaxel
Open the PDF for Association of the <em>CYP1B1*3</em> allele with survival in patients with prostate cancer receiving docetaxel in another window
Journal Articles

Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel

Tristan Sissung, Romano Danesi, Douglas Price, Seth Steinberg, Ronald de Wit, Kathryn Compton, Muhammad Zahid, Nilesh Gaikwad, Ercole Cavalieri, William Dahut, Dan Sackett, William Figg, Alex Sparreboom
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): C128.
Published: 01 November 2007
View article titled, Association of the <em>CYP1B1*3</em> allele with survival in patients with prostate cancer receiving docetaxel